(Q39021015)

8 September 2017

0 references

ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis (English)

1 reference

8 September 2017

1 reference

Bertram Müller-Myhsok

4

object named as

Bertram Müller-Myhsok

1 reference

8 September 2017

5

Florian Holsboer

1 reference

8 September 2017

Barbara Breitenstein

1

1 reference

8 September 2017

Tanja Maria Brückl

2

1 reference

8 September 2017

Marcus Ising

3

1 reference

8 September 2017

Darina Czamara

6

1 reference

8 September 2017

language of work or name

1 reference

2 April 2015

1 reference

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

8 September 2017

published in

1 reference

8 September 2017

volume

168B

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

274-283

1 reference

ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

How can we realize the promise of personalized antidepressant medicines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Non-compliance with digoxin in patients with heart failure and/or atrial fibrillation: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Antidepressants and ABCB1 Gene C3435T Functional Polymorphism: A Naturalistic Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Pharmacogenetics in major depression: a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Pharmacogenetic studies in depression: a proposal for methodologic guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32309

21 January 2018

Identifiers

DOI

10.1002/AJMG.B.32309

1 reference

8 September 2017

1 reference